Abstract 16263: Liver Fibrosis Staging by FIB-4 Index Predicts Incident Heart Failure, MACE, and Mortality in MASLD: Implications for the AHA Cardiovascular-Kidney-Metabolic Framework
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults globally, and cardiovascular disease is the leading cause of death in this population. The Fibrosis-4 (FIB-4) index has been validated as an independent predictor of MACE and HF hospitalization beyond traditional risk factors. The AHA's 2023 CKM Health framework incorporated MASLD into Stage 3, yet CKM risk equations include no liver fibrosis marker. The AHA's 2025 HF Prevention Scientific Statement explicitly calls for screening for pre-heart failure in MASLD patients. This study examined whether FIB-4 stratification demonstrates a graded association with incident cardiovascular outcomes in adults with MASLD and cardiometabolic risk factors. Methods: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (67 healthcare organizations). Adults ≥18 years with MASLD and ≥1 cardiometabolic risk factor (obesity, type 2 diabetes, hypertension, or dyslipidemia) were stratified into three cohorts by FIB-4: <1.3 (n=273,698), 1.3-2.67 (n=154,811), and ≥2.67 (n=21,161). Patients with pre-existing HF, MI, stroke, alcohol-related or viral liver disease, or decompensated cirrhosis were excluded. Three pairwise propensity score matched analyses were performed, balancing age, sex, comorbidities, and smoking status. Outcomes included MACE (AMI, stroke, cerebrovascular disease, PCI), incident HF, atrial fibrillation (AF), hepatic decompensation, and all-cause mortality. Kaplan-Meier survival analysis and Cox proportional hazards models were used. P<0.05 was considered significant.Results:After matching, cohorts included 63,344/group (<1.3 vs 1.3-2.67), 4,977/group (<1.3 vs ≥2.67), and 20,747/group (1.3-2.67 vs ≥2.67). Mean age after matching was 39.6 years for low-vs-intermediate and 61.0 years for intermediate-vs-high. A graded dose-response was observed across all outcomes. MACE: risk 0.9% vs 1.4% vs 3.5%; HR 1.23 (95% CI 1.11-1.37, p<0.001) for 1.3-2.67 and HR 3.36 (2.38-4.74, p<0.001) for ≥2.67. Incident HF: HR 1.15 (1.05-1.25, p=0.002) for 1.3-2.67; HR 1.90 (1.70-2.11, p<0.001) for ≥2.67 vs 1.3-2.67. AF: HR 1.61 (1.44-1.79, p<0.001) for ≥2.67 vs 1.3-2.67. All-cause mortality showed the steepest gradient: 1.3% vs 1.5% vs 29.9%; HR 5.18 (4.88-5.49, p<0.001) for ≥2.67 vs 1.3-2.67. Hepatic decompensation was 15-fold higher in ≥2.67 vs 1.3-2.67 (HR 16.26, p<0.001). Conclusion: In a large multi-institutional cohort, FIB-4 demonstrated a graded, independent association with incident MACE, HF, AF, and all-cause mortality in MASLD. These findings support incorporating FIB-4 based fibrosis staging into cardiovascular risk assessment within the AHA CKM framework and reinforce the need for targeted HF screening in patients with elevated FIB-4 scores.